3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Anemia
4
Multiple Myeloma
3
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Recurrence
1
Primary Myelofibrosis
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
155
Gemcitabine
139
Capecitabine
121
Paclitaxel
118
Fluorouracil
116
Oxaliplatin
110
Bevacizumab
104
Nivolumab
97
Leucovorin
97
Docetaxel
92
Cisplatin
89
Irinotecan
87
Carboplatin
84
Radiosurgery
83
Cyclophosphamide
70
Cetuximab
70
Magnetic Resonance Spectroscopy
68
Trastuzumab
56
Specimen Handling
56
Biopsy
56
Radiotherapy
55
Ipilimumab
52
Everolimus
48
Pemetrexed
46
Drug Therapy
45
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
43
Doxorubicin
41
Fulvestrant
38
aldesleukin
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasm Metastasis
×
ACE-011
×
Clear all
NCT00931606
2023-09-13
MK-7962-012
Merck Sharp & Dohme LLC
Phase 2
Terminated
30 enrolled
32 charts